SLS insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Burns John Thomas CFO · SELLAS Life Sciences Group, Inc. | SLS SELLAS Life Sciences Group, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 558893 · SEC code covers open-market or private transactions · Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the performance based vesting of certain previously granted restricted stock units upon meeting the primary endpoint in the Issuer's Phase 3 REGAL study. These sales are mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. | 2026-11-18 | 2026-11-20 | ≈ $73,470.92 3,831 shares/units | SEC 4 | Follow |
| CICIC DRAGAN SVP, Chief Development Officer · SELLAS Life Sciences Group, Inc. | SLS SELLAS Life Sciences Group, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 557361 · SEC code covers open-market or private transactions · Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the performance based vesting of certain previously granted restricted stock units upon meeting the primary endpoint in the Issuer's Phase 3 REGAL study. These sales are mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. | 2026-11-18 | 2026-11-20 | ≈ $132,961.07 6,933 shares/units | SEC 4 | Follow |
| Stergiou Angelos M. President and CEO · Director · SELLAS Life Sciences Group, Inc. | SLS SELLAS Life Sciences Group, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 1734896 · SEC code covers open-market or private transactions · Represents shares sold to satisfy the Reporting Person's tax withholding obligation in connection with the performance based vesting of certain previously granted restricted stock units upon meeting the primary endpoint in the Issuer's Phase 3 REGAL study. These sales are mandated as part of the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. | 2026-11-18 | 2026-11-20 | ≈ $510,249.87 26,606 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.